Janssen Collaborates With ViiV Healthcare to Develop Two-Drug Single Tablet Regimen for the Maintenance Treatment of People Living With HIV
Cork, Ireland (ots/PRNewswire) - Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT(R)) and ViiV's ...